ALK-Abelló A/S (CPH: ALK.B)
Denmark
· Delayed Price · Currency is DKK 161.30
+6.50 (4.20%)
Dec 20, 2024, 4:59 PM CET
ALK-Abelló Revenue
ALK-Abelló had revenue of 1.31B DKK in the quarter ending September 30, 2024, with 18.29% growth. This brings the company's revenue in the last twelve months to 5.38B, up 13.85% year-over-year. In the year 2023, ALK-Abelló had annual revenue of 4.82B with 6.94% growth.
Revenue (ttm)
5.38B
Revenue Growth
+13.85%
P/S Ratio
6.63
Revenue / Employee
1.93M
Employees
2,824
Market Cap
35.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.82B | 313.00M | 6.94% |
| Dec 31, 2022 | 4.51B | 595.00M | 15.19% |
| Dec 31, 2021 | 3.92B | 425.00M | 12.17% |
| Dec 31, 2020 | 3.49B | 217.00M | 6.63% |
| Dec 31, 2019 | 3.27B | 359.00M | 12.32% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk A/S | 270.58B |
| Coloplast A/S | 27.03B |
| Genmab A/S | 19.84B |
| Demant A/S | 22.84B |
| Zealand Pharma A/S | 76.87M |
| H. Lundbeck A/S | 21.44B |
| H. Lundbeck A/S | 21.44B |
| Ambu A/S | 5.39B |
ALK-Abelló News
- 4 weeks ago - Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins - GuruFocus